PL3670522T3 - Krystaliczna postać chlorku rybozydu nikotynamidu - Google Patents

Krystaliczna postać chlorku rybozydu nikotynamidu

Info

Publication number
PL3670522T3
PL3670522T3 PL20153772T PL20153772T PL3670522T3 PL 3670522 T3 PL3670522 T3 PL 3670522T3 PL 20153772 T PL20153772 T PL 20153772T PL 20153772 T PL20153772 T PL 20153772T PL 3670522 T3 PL3670522 T3 PL 3670522T3
Authority
PL
Poland
Prior art keywords
crystalline form
nicotinamide riboside
riboside chloride
chloride
nicotinamide
Prior art date
Application number
PL20153772T
Other languages
English (en)
Inventor
Erik C. Carlson
Michael C. Standen
Westin M. Morrill
Original Assignee
W.R. Grace & Co. - Conn.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55163976&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3670522(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by W.R. Grace & Co. - Conn. filed Critical W.R. Grace & Co. - Conn.
Publication of PL3670522T3 publication Critical patent/PL3670522T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/048—Pyridine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL20153772T 2014-07-24 2015-07-24 Krystaliczna postać chlorku rybozydu nikotynamidu PL3670522T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462028702P 2014-07-24 2014-07-24
PCT/US2015/041956 WO2016014927A2 (en) 2014-07-24 2015-07-24 Crystalline form of nicotinamide riboside
EP20153772.7A EP3670522B1 (en) 2014-07-24 2015-07-24 Crystalline form of nicotinamide riboside chloride
EP15825253.6A EP3174891B1 (en) 2014-07-24 2015-07-24 Crystalline form of nicotinamide riboside

Publications (1)

Publication Number Publication Date
PL3670522T3 true PL3670522T3 (pl) 2022-02-21

Family

ID=55163976

Family Applications (2)

Application Number Title Priority Date Filing Date
PL15825253T PL3174891T3 (pl) 2014-07-24 2015-07-24 Krystaliczna postać rybozydu nikotynamidu
PL20153772T PL3670522T3 (pl) 2014-07-24 2015-07-24 Krystaliczna postać chlorku rybozydu nikotynamidu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL15825253T PL3174891T3 (pl) 2014-07-24 2015-07-24 Krystaliczna postać rybozydu nikotynamidu

Country Status (7)

Country Link
US (2) US10323058B2 (pl)
EP (2) EP3174891B1 (pl)
CN (1) CN106715454B (pl)
CA (1) CA2956163C (pl)
ES (2) ES2908332T3 (pl)
PL (2) PL3174891T3 (pl)
WO (1) WO2016014927A2 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2963057T3 (es) * 2015-03-09 2024-03-25 Grace W R & Co Forma cristalina de ribósido de nicotinamida
US9855289B2 (en) 2015-08-05 2018-01-02 Metro International Biotech, Llc Nicotinamide mononucleotide derivatives and their uses
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
EP3429354A4 (en) 2016-03-16 2020-03-25 Chromadex Inc. B-VITAMIN AND AMINO ACID CONJUGATES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, DERIVATIVES THEREOF AND METHOD FOR THE PRODUCTION THEREOF
WO2017218580A1 (en) 2016-06-14 2017-12-21 Rejuvenation Therapeutics Corporation Synthetic methods for the preparation of nicotinamide riboside and related compounds
NZ803738A (en) 2016-11-11 2024-05-31 Chromadex Inc Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof
EP3554285A4 (en) 2016-11-29 2021-01-20 University of Iowa Research Foundation USE OF NAD PRECURSORS TO IMPROVE THE HEALTH OF MOTHER AND / OR OFFspring
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
US20190328761A1 (en) 2016-12-21 2019-10-31 Newsouth Innovations Pty Limited Methods for enhancing vascular density
US11286274B2 (en) 2017-06-19 2022-03-29 Mitopower Llc Nicotinamide riboside derivatives and their uses
EP3727400A4 (en) * 2017-12-22 2021-10-20 Elysium Health, Inc. CRYSTALLINE FORMS OF NICOTINAMIDE RIBOSIDE CHLORIDE
WO2019152416A1 (en) 2018-01-30 2019-08-08 Metro International Biotech, Llc Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
CN112135833A (zh) * 2018-05-18 2020-12-25 弗·哈夫曼-拉罗切有限公司 (硫代)烟酰胺呋喃核糖苷盐及其组合物、制备方法和用途
CN108774278A (zh) * 2018-09-10 2018-11-09 张洪喜 一种制备尼克酰胺核苷盐的方法
KR20210108400A (ko) 2018-12-10 2021-09-02 크로마덱스 아이엔씨. 니코티노일 리보사이드 및 이의 유도체의 결정질 형태 및 이의 제조 방법
WO2020131578A2 (en) 2018-12-17 2020-06-25 Mitopower Llc Nicotinyl riboside compounds and their uses
EP3927715A4 (en) 2019-02-21 2023-03-01 Chromadex, Inc. USE OF NICOTINAMIDE RIBOSIDE, NICOTINOIC ACID RIBOSIDE, REDUCED NICOTINYL RIBOSIDE COMPOUNDS AND NICOTINYL RIBOSIDE COMPOUNDS IN FORMULATIONS
US10618927B1 (en) 2019-03-22 2020-04-14 Metro International Biotech, Llc Compositions and methods for modulation of nicotinamide adenine dinucleotide
US11939348B2 (en) 2019-03-22 2024-03-26 Metro International Biotech, Llc Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide
JP7675061B2 (ja) 2019-07-19 2025-05-12 バイオシント アクチェンゲゼルシャフト ニコチンアミドリボフラノシド塩の製造方法、ニコチンアミドリボフラノシド塩自体、およびその使用
CN111808156A (zh) * 2020-07-15 2020-10-23 许昌远志生物科技有限公司 一种β-烟酰胺核糖氯化物的晶型1A、晶型1B及其制备方法
CA3187278A1 (en) * 2020-09-15 2022-03-24 Societe Des Produits Nestle S.A. Methods for producing dihydronicotinamide riboside from nicotinamide riboside chloride
CA3219033A1 (en) 2021-05-27 2022-12-01 Metro International Biotech, Llc Crystalline solids of nicotinic acid mononucleotide and esters thereof and methods of making and use

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1190080A (en) 1966-08-08 1970-04-29 Kyowa Hakko Kogyo Company Ltd Process for producing Nicotinamide Adenine Dinucleotide
US3728111A (en) 1971-09-21 1973-04-17 Asea Ab Method of manufacturing billets from powder
EP0981534B1 (en) 1997-02-06 2006-05-03 Inspire Pharmaceuticals, Inc. Dinucleotides and their uses
GB9712370D0 (en) 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
JP2005502580A (ja) 2000-12-15 2005-01-27 フアーマセツト・リミテツド フラビウィルス感染治療用抗ウィルス薬
US7179791B2 (en) 2001-01-11 2007-02-20 Duke University Inhibiting GS-FDH to modulate NO bioactivity
US7977049B2 (en) * 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US20050020587A1 (en) 2003-07-25 2005-01-27 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
EP1723227A4 (en) 2004-02-10 2007-09-19 Dartmouth College NICOTINAMIDRIBOSIDE KINASE COMPOSITIONS AND METHOD FOR THEIR USE
US8114626B2 (en) 2004-02-10 2012-02-14 Trustees Of Dartmouth College Yeast strain and method for using the same to produce nicotinamide riboside
CN1964627B (zh) 2004-06-04 2011-10-19 华盛顿大学 治疗神经病变的方法和组合物
ES2430569T3 (es) 2005-02-18 2013-11-21 Astrazeneca Ab Compuestos antibacterianos derivados de piperidina
EP2805719A1 (en) * 2005-03-30 2014-11-26 Glaxosmithkline LLC Nicotinamide riboside and analogues thereof
US20070149466A1 (en) 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
WO2007061798A2 (en) * 2005-11-18 2007-05-31 Cornell Research Foundation, Inc. Nicotinoyl riboside compositions and methods of use
US20070248590A1 (en) 2005-12-02 2007-10-25 Sirtris Pharmaceuticals, Inc. Modulators of CDC2-like kinases (CLKS) and methods of use thereof
WO2007136744A1 (en) 2006-05-19 2007-11-29 The Johns Hopkins University Crystal structure of a substrate complex of nampt/pbef/visfatin
JP2010513458A (ja) * 2006-12-19 2010-04-30 ファイザー・プロダクツ・インク Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体、およびプロスタグランジンｄ２の仲介による疾患を治療するためのその使用
CA2676609A1 (en) 2007-01-26 2008-07-31 Washington University Methods and compositions for treating neuropathies
EP2307378A1 (en) * 2008-06-18 2011-04-13 Pfizer Limited Nicotinamide derivatives
US20100015072A1 (en) 2008-06-30 2010-01-21 Christopher Polla Topical Compositions Comprising Isonicotinamide
WO2010017374A1 (en) 2008-08-06 2010-02-11 Sicor Inc. Process for preparing azacytidine intermediate
WO2011005289A2 (en) 2009-06-23 2011-01-13 President And Fellows Of Harvard College Methods and kits for measuring enzyme activity
WO2011011721A2 (en) 2009-07-24 2011-01-27 Amazentis Sa Compounds, compositions and methods for protecting brain health in neurodegenerative disorders
US8507251B2 (en) 2009-09-28 2013-08-13 Robert J. Greenstein Medium and method for culturing Mycobacterium avium subspecies paratuberculosis
WO2011081942A1 (en) * 2009-12-14 2011-07-07 Cornell University Activation and activators of sirt5
EP2464249B1 (de) 2010-03-29 2013-03-13 Johannes Huber Konzentrationssteigerndes getränk
US8481711B2 (en) 2010-07-06 2013-07-09 Hidenori Kamanishi Neurite outgrowth agent
WO2012114204A2 (en) 2011-02-15 2012-08-30 Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto Methods of treating mitochondrial dysfunction
US20120107888A1 (en) 2011-02-17 2012-05-03 Qteros, Inc. Modulation of fermentation products through vitamin supplementation
US20120328526A1 (en) 2011-06-27 2012-12-27 University Of Maryland, Baltimore Modulation of Nad+ Activity in Neuropathophysiological Conditions and Uses Thereof
EP3345901A3 (en) 2011-06-29 2018-09-12 President and Fellows of Harvard College Small molecules as antiaging agents
EP2726601B1 (en) 2011-06-29 2018-12-26 The General Hospital Corporation Compositions and methods for enhancing bioenergetic status in female germ cells
US20140256760A1 (en) 2012-07-09 2014-09-11 Noglo Llc Reduction or prevention of alcohol reaction with dietary supplements
EP2869717B8 (en) 2012-07-09 2018-07-25 NoGlo, Inc. Prevention of alcohol reaction with dietary supplements
EP2872128B1 (en) 2012-07-16 2020-02-19 Cornell University Nicotinamide riboside to treat hearing loss
WO2014059029A1 (en) 2012-10-09 2014-04-17 President And Fellows Of Harvard College Treatment of age-related and mitochondrial diseases by inhibition of hif-1 alpha function
WO2014111906A1 (en) 2013-01-21 2014-07-24 Ecole Polytechnique Federale De Lausanne (Epfl) Bioluminescence imaging of small biomolecules
SG11201507046UA (en) 2013-03-15 2015-10-29 Nusirt Sciences Inc Leucine and nicotinic acid reduces lipid levels
GB201313465D0 (en) * 2013-07-29 2013-09-11 Queens University Of The Belfast Methods of preparing nicotinamide riboside and derivatives thereof
WO2015061512A1 (en) 2013-10-24 2015-04-30 The Procter & Gamble Company Skin lightening cosmetic compositions and methods
WO2015064988A1 (ko) 2013-10-29 2015-05-07 한림대학교 산학협력단 니코틴아마이드 라이보사이드를 유효성분으로 포함하는 패혈증 치료 또는 예방용 약제학적 조성물
JP6509844B2 (ja) 2013-10-30 2019-05-08 クロマデックス, インコーポレイテッドChromaDex, Inc. 皮膚症状の治療において局所使用されるニコチンアミドリボシド組成物
BR112016010422B1 (pt) 2013-11-12 2021-08-31 Ortho-Nutra, Llc Suplemento dietético e método de tratamento para melhorar o desempenho ou energia física em um indivíduo
WO2015099842A1 (en) 2013-12-23 2015-07-02 Abbott Laboratories Hot beverage fortifier
JP2017511304A (ja) 2014-03-13 2017-04-20 ソーク インスティチュート フォー バイオロジカル スタディーズ フェキサラミン類似体ならびに作製方法および使用方法
CA2942403A1 (en) 2014-03-13 2015-09-17 Salk Institute For Biological Studies Fxr agonists and methods for making and using
US20150297508A1 (en) 2014-04-21 2015-10-22 William Andriette Topical Formulation to Enhance Genital Sensation and Function
US10316054B2 (en) * 2014-06-02 2019-06-11 Glaxosmithkline Intellectual Property (No. 2) Limited Preparation and use of crystalline beta-D-nicotinamide riboside
RU2016149767A (ru) 2014-06-06 2018-07-16 Глэксосмитклайн Интеллекчуал Проперти (Но.2) Лимитед Аналоги никотинамидрибозида и фармацевтические композиции и их применение
WO2016011360A1 (en) 2014-07-17 2016-01-21 The Scripps Research Institute Methods and compositions for enhancing cancer therapy
ES2963057T3 (es) 2015-03-09 2024-03-25 Grace W R & Co Forma cristalina de ribósido de nicotinamida

Also Published As

Publication number Publication date
US20170210774A1 (en) 2017-07-27
ES2908332T3 (es) 2022-04-28
EP3174891A4 (en) 2018-05-30
ES2776395T3 (es) 2020-07-30
CN106715454A (zh) 2017-05-24
US10323058B2 (en) 2019-06-18
PL3174891T3 (pl) 2020-08-10
US10233207B2 (en) 2019-03-19
EP3670522A1 (en) 2020-06-24
EP3174891B1 (en) 2020-01-29
EP3174891A2 (en) 2017-06-07
CA2956163A1 (en) 2016-01-28
EP3670522B1 (en) 2022-01-19
WO2016014927A2 (en) 2016-01-28
WO2016014927A3 (en) 2016-09-15
CA2956163C (en) 2023-01-10
CN106715454B (zh) 2020-06-16
US20180086783A1 (en) 2018-03-29

Similar Documents

Publication Publication Date Title
ZA201705776B (en) Crystalline form of nicotinamide riboside
PL3174891T3 (pl) Krystaliczna postać rybozydu nikotynamidu
GB2542881B (en) Crystal forms of ß-nicotinamide mononucleotide
ZA201608843B (en) Chloride salt of tat-nr2b9c
GB201402650D0 (en) Method of producing graphene
IL248529B (en) Palladianolide pyridine compounds and methods of use
SI3380554T2 (sl) Kristalne oblike per-kloro-gama-ciklodekstrinov
SG10202101979TA (en) Crystalline forms of c21h22ci2n4o2
PL3113773T3 (pl) Krystaliczne postaci grapiprantu
PL3529236T3 (pl) Krystaliczne formy erawacykliny
IL251863A0 (en) Crystalline forms of ferric-maltol
EP3207034A4 (en) Anhydrous crystalline form of s-equol
IL253479A0 (en) Crystalline forms of efinconazole
GB2556529B (en) Methods of drilling
HUP1500506A2 (en) Salts of palbociclib